ABC | Volume 112, Nº4, Abril 2019

Artigo Original de Faria et al Escore inflamatório e hipertensão resistente Arq Bras Cardiol. 2019; 112(4):383-389 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 11. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-6. 12. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway . Circulation. 2000;102(11):1296-301. 13. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. BiochemBiophys Res Commun. 2003;301(4):1045-50. 14. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 1996;97(9):2152-7. 15. Machleidt F, Simon P, Krapalis AF, Hallschmid M, Lehnert H, Sayk F. Experimentalhyperleptinemiaacutely increasesvasoconstrictorysympathetic nerveactivityinhealthyhumans.JClinEndocrinolMetab.2013;98(3):E491-6. 16. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement fromtheAmericanHeartAssociationProfessionalEducationCommitteeofthe CouncilforHighBloodPressureResearch.Hypertension.2008;51(6):1403-19. 17. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. 18. de Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar- Toledo JC, MorenoH. Intensivemonitoring of adherence to treatment helps to identify “true” resistant hypertension. J Clin Hypertens (Greenwich). 2009;11(4):183-91. 19. de Haro Moraes C, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T, et al. High-circulating leptin levels are associatedwith increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens. 2013;27(4):225-30. 20. Boer-Martins L, Figueiredo VN, Demacq C, Martins LC, Consolin-Colombo F, Figueiredo MJ, et al. Relationship of autonomic imbalance and circadian disruptionwith obesity and type 2 diabetes in resistant hypertensive patients. Cardiovasc Diabetol. 2011 Mar 22;10:24. 21. Catharina AS, Modolo R, Ritter AMV, Sabbatini AR, Lopes HF, Moreno Junior H, Faria AP. Metabolic Syndrome-Related Features in Controlled and Resistant Hypertensive Subjects. Arq Bras Cardiol. 2018 Jun;110(6):514-521. 22. Enkhmaa B, Anuurad E, Zhang W, Kim K, Berglund L. Diverging trajectory patterns of systemic versus vascular inflammation over age in healthy Caucasians and African-Americans . Atherosclerosis. 2015;239(2):509-15. 23. Filho AG, Kinote A, Pereira DJ, Rennó A, dos Santos RC, Ferreira-Melo SE, et al. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats. Eur J Pharmacol. 2013;700(1-3):201-9. 24. Kirabo A, Fontana V, de Faria AP, Loperena R, Galindo CL, Wu J, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124(10):4642-56. 25. Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, et al. The inflammatory status score including IL-6, TNF-alpha, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 2014;51(1):123-31. 26. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289(14):1799-804. 27. Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance . Obes Res. 2003;11(9):1048-54. 28. Scalia, R. The microcirculation in adipose tissue inflammation. Rev Endocr Metab Disord. 2013;14(1):69-76. 29. BakkerW,SipkemaP,StehouwerCD,SerneEH,SmuldersYM,vanHinsbergh VW, et al. Protein kinase C theta activation induces insulin-mediated constriction of muscle resistance arteries . Diabetes. 2008;57(3):706-13. 30. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling fromperivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365(9473):1817-20. 31. Rossi M, Nannipieri M, AnselminoM, PesceM, Muscelli E, Santoro G, et al. Skin vasodilator function and vasomotion in patients with morbid obesity: effects of gastric bypass surgery . Obes Surg. 2011;21(1):87-94. 32. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium . Curr Diab Rep. 2003;3(4):279-88. 33. Landmesser U, Drexler H. Endothelial function and hypertension.Curr Opin Cardiol. 2007;22(4):316-20. 34. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104(2):191-6. 35. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2002;22(9):e19-23. 36. Koh KK, Schenke WH, Waclawiw MA, Csako G, Cannon RO 3rd. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation. 2002;105(13):1531-3. 37. Koh KK, Ahn JY, Han SH, KimDS, JinDK, KimHS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients . J Am Coll Cardiol. 2003;42(5):905-10. 38. Trevelyan J, Brull DJ, Needham EW, Montgomery HE, Morris A, Mattu RK. Effect of enalapril and losartan on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting and their interaction with polymorphisms in the interleukin-6 gene. Am J Cardiol. 2004;94(5):564-9. 39. GuoC,RicchiutiV,LianBQ,YaoTM,CoutinhoP,RomeroJR,etal.Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisomeproliferator-activatedreceptor-gamma,andproinflammatoryadipokines. Circulation.2008;117(17):2253-61. 40. TrøseidM, Lappegård KT, Claudi T, Damås JK, Mørkrid L, Brendberg R, et al. Exercise reduces plasma levels of the chemokinesMCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J. 2004;25(4):349-55. 41. Hu P, Thinschmidt JS, Yan Y, Hazra S, Bhatwadekar A, Caballero S, et al. CNS inflammation and bonemarrowneuropathy in type 1 diabetes. Am J Pathol. 2013;183(5):1608-20. 42. Santisteban MM, Ahmari N, Carvajal JM, Zingler MB, Qi Y, Kim S, et al. Involvement of bonemarrow cells and neuroinflammation in hypertension . Circ Res. 2015;117(2):178-91. 43. LiuW, Wang X, FengW, Li S, TianW, Xu T, et al. Lentivirus mediated IL-17R blockade improves diastolic cardiac function in spontaneously hypertensive rats. Exp Mol Pathol. 2011;91(1):362-7. 389